항감염제 : 시장 인사이트, 역학, 시장 예측(2030년)

Anti-Infective Drugs Market by Type (Antibiotics, Antivirals, Antifungals, and Others), Indication (HIV Infection, Pneumonia, Respiratory Viral Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of various targeted diseases such as healthcare-associated infections, sexually transmitted diseases, respiratory infections, and others, the increasing research & developmental activities and ongoing clinical trials concerning to the anti-infective drugs, and the increased number of drug approval across the globe.

The anti-infective drugs market was valued at USD 134.87 billion in 2023, growing at a CAGR of 4.38% during the forecast period from 2024 to 2030 to reach USD 175.94 billion by 2030. The market for anti-infective drugs is experiencing robust growth driven by several interconnected factors. Firstly, there is a notable increase in the prevalence of targeted infectious diseases such as healthcare-associated infections, sexually transmitted diseases (STDs), and respiratory infections. These conditions pose significant public health challenges globally, compelling healthcare systems to prioritize effective treatment options. Concurrently, ongoing research and developmental activities and clinical trials in the field are intensifying, aimed at innovating new therapies and enhancing the efficacy of existing drugs. Moreover, the regulatory landscape has become more favorable, with a growing number of anti-infective drugs receiving approvals across various regions worldwide. This trend not only expands patient access to essential treatments but also encourages pharmaceutical companies to invest in novel drug development. Thus, these factors collectively boost the anti-infective drugs market, during the forecast period from 2024 to 2030.

Anti-Infective Drugs Market Dynamics:

According, to the latest data provided by the World Health Organization (WHO) (2022), globally, healthcare-associated infections (HAIs) affect hundreds of millions annually, with 7 out of every 100 patients in high-income countries and 15 in low- and middle-income countries acquiring at least one HAI in acute care hospitals. In the EU/EEA, 8.9 million HAIs occur each year in acute and long-term care facilities. These alarming statistics highlight the critical need for infection prevention measures, promoting the demand for anti-infective drugs. This demand encompasses a range of pathogens, including antibiotic-resistant bacteria and hospital-adapted strains, necessitating advanced drugs that can effectively combat these challenges. Pharmaceutical companies are thus incentivized to innovate and develop new anti-infective drugs that not only treat HAIs but also address emerging resistance patterns, contributing to the expansion and evolution of the anti-infective drug market.

According to the recent update provided by the World Health Organization (2024), globally, more than 1 million curable sexually transmitted infections (STIs) are acquired daily among individuals aged 15-49, with the majority being asymptomatic. In 2022, an estimated 8 million adults within this age group were infected with syphilis, contributing to over 390,000 adverse birth outcomes from 1.1 million estimated cases among pregnant women. Additionally, as of 2022, approximately 254 million people were living with hepatitis B worldwide. Thus, the asymptomatic nature of most cases and the potential for severe complications, especially among vulnerable populations like pregnant women, emphasize the necessity for innovative anti-infective drugs to address these challenges. As pharmaceutical companies continue to invest in research and development to combat STDs and their complications, the market for anti-infective drugs is poised for growth, driven by the imperative to provide effective treatments and mitigate the spread of these infectious diseases globally.

Furthermore, successful clinical trials contribute to expanding treatment options, addressing unmet medical needs also boosting the market. For instance, in June 2024, Gilead Sciences, Inc. announced topline results from an interim analysis of its pivotal Phase 3 PURPOSE 1 trial, which indicated that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, had demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. Thus, the success of ongoing clinical trials for anti-infective drugs plays a pivotal role in driving market growth and innovation within the pharmaceutical industry. These trials, aimed at evaluating the safety and efficacy of new treatments against infectious diseases such as bacterial infections, viral outbreaks, and emerging pathogens, generate crucial data that can lead to regulatory approvals and market entry thereby boosting the overall market of anti-infective drugs.

Therefore, the factors stated above collectively will drive the overall anti-infective drugs market throughout the forecast period from 2024 to 2030.

However, the emergence and spread of drug-resistant pathogens along with the side effects and the stringent regulatory approval may hinder the growth of anti-infective drugs during the forecast period.

Anti-Infective Drugs Market Segment Analysis:

Anti-Infective Drugs Market by Type (Antibiotics, Antivirals, Antifungals, and Others), Indication (HIV Infection, Pneumonia, Respiratory Viral Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the anti-infective drugs market, the antibiotics category is estimated to have a significant revenue share in the anti-infective drug market in 2023. Antibiotics play a pivotal role in boosting the overall market of anti-infective drugs by addressing a significant portion of the global infectious disease burden. As primary treatments for bacterial infections, antibiotics are indispensable in both acute and chronic care settings, treating a wide range of conditions from common ailments like strep throat and urinary tract infections to severe diseases such as sepsis and bacterial pneumonia. The continuous emergence of antibiotic-resistant bacteria necessitates the development of novel antibiotics, driving research and innovation within the pharmaceutical industry. Furthermore, antibiotics' critical role in surgical prophylaxis, cancer therapy support, and management of hospital-acquired infections underscores their essentiality in modern medicine. This persistent demand for effective antibiotics fosters substantial market growth, as healthcare providers, policymakers, and pharmaceutical companies invest in discovering and deploying new antibiotic therapies. As a result, the antibiotic segment significantly contributes to the expansion and dynamism of the broader anti-infective drug market, ensuring robust treatment options and advancing public health initiatives globally.

The market expansion of antibiotics is also fueled by ongoing drug approval by regulatory bodies across the globe. For instance, in April 2024, The FDA approved a new antibiotic, Zevtera (ceftobiprole medocaril sodium for injection), for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis. Additionally, it is approved for adults with acute bacterial skin and skin structure infections (ABSSSI) and adult and pediatric patients aged three months to less than 18 years with community-acquired bacterial pneumonia (CABP).

Therefore, owing to the above-mentioned factors, the demand for antibiotics upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global anti-infective drugs market during the forecast period.

North America is expected to dominate the overall anti-infective drugs market:

North America is expected to account for the highest proportion of the anti-infective drugs market in 2023, out of all regions. This can be ascribed to the increasing demand for anti-infective drugs in the region owing to the increasing prevalence of many infectious and targeted diseases, the increasing geriatric patient pool suffering from infectious and targeted diseases, the growing initiatives for the awareness of infectious diseases, the launch of new drugs, and the presence of key market players in the region driving the anti-infective drugs market in North America.

According to the recent data provided by the U.S. Department of Health and Human Services (2021), about 1 in 31 inpatients have an infection related to hospital care in the United States. Thus, healthcare-associated infections, further fuels the adoption of advanced stopcocks with features that minimize contamination risks in the United States.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (CDC), in 2022, individuals aged 13 to 34 accounted for more than half (60%) of the estimated new HIV infections. Additionally as per the same source, according to the latest update of 2024, there have been at least 35 million cases of illness, 390,000 hospitalizations, and 25,000 deaths due to the flu. Thus, as the healthcare systems strive to manage these widespread infections, pharmaceutical companies are incentivized to invest in research and development of new and more effective anti-infective treatments, thus expanding the market. This heightened focus on combating HIV and flu not only addresses urgent public health needs but also fosters growth and innovation in the anti-infective drug sector thereby boosting the market.

Further, the United States CDC promotes the use of antivirals for various infectious diseases. For instance, in September 2021, the CDC published a brochure supporting the use of antiviral drugs for the treatment of influenza. The CDC suggested the use of four drugs approved by the FDA, oseltamivir phosphate, zanamivir, peramivir, and baloxavir marboxil. Thus, such activities by governmental health organizations promoting the use of antivirals in the nation are expected to propel the growth of the anti-infective drugs market during the forecast period.

Moreover, the anti-infective drug launches, regulatory approvals, and other activities such as acquisitions, and agreements, in the region will lead to its increased demand in the market. For instance, in January 2022, Alembic Pharmaceuticals received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets. Doxycycline Hyclate Delayed-Release tablets are indicated to reduce the development of drug-resistant bacteria.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the anti-infective drugs market.

Anti-Infective Drugs Market Key Players:

Some of the key market players operating in the Anti-Infective Drugs market include Merck & Co., Inc., Gilead Sciences, Inc., GSK plc., Pfizer Inc., Alembic Pharmaceuticals, Mankind Pharma, Novartis AG, Abbott., Astellas Pharma d.o.o., Bayer AG, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Cipla Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Xellia Pharmaceuticals, AbbVie Inc., Melinta Therapeutics LLC, PACIFIC INDIA PHARMA LIMITED, and others.

Recent Developmental Activities in the Anti-Infective Drugs Market:

• In May 2023, the U.S. Food and Drug Administration approved Arexvy, the first vaccine for respiratory syncytial virus (RSV) available in the United States. Arexvy is approved for preventing lower respiratory tract disease caused by RSV in individuals aged 60 and older.
• In May 2023, the Food and Drug Administration approved Xacduro (sulbactam for injection; durlobactam for injection), a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex, for patients 18 years of age and older.
• In December 2022, the FDA approved Sunlenca(R) (lenacapavir) as a first-in-class, twice-yearly treatment option for individuals living with multi-drug resistant HIV.

Key takeaways from the Anti-infective Drugs market report study:

• Market size analysis for current anti-infective drugs size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the anti-infective drugs market.
• Various opportunities available for the other competitors in the anti-infective drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current anti-infective drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for anti-infective drugs market growth in the coming future?

Target audience who can be benefited from this Anti-Infective Drugs market report study:

• Anti-infective drug product providers
• Research organizations and consulting companies
• Anti-infective drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in anti-infective drugs
• Various end-users who want to know more about the anti-infective drugs market and the latest technological developments in the anti-infective drugs market.

Frequently Asked Questions for the Anti-Infective Drugs Market:

1. What are anti-infective drugs?

Anti-infective drugs are medications designed to prevent and treat infections caused by various pathogens, including bacteria, viruses, fungi, and parasites. These drugs encompass a wide range of classes, such as antibiotics for bacterial infections, antivirals for viral infections, antifungals for fungal infections, and antiparasitics for parasitic infections. By targeting and eliminating infectious agents or inhibiting their growth, anti-infective drugs play a crucial role in managing and preventing diseases, thereby safeguarding public health and improving patient outcomes.

2. What is the market for anti-infective drugs?

The global anti-infective drugs market was valued at USD 134.87 billion in 2023, growing at a CAGR of 4.38% during the forecast period from 2024 to 2030 to reach USD 175.94 billion by 2030.

3. What are the drivers for the anti-infective drugs market?

The market for anti-infective drugs is experiencing robust growth driven by several interconnected factors. Firstly, there is a notable increase in the prevalence of targeted infectious diseases such as healthcare-associated infections, sexually transmitted diseases (STDs), and respiratory infections. These conditions pose significant public health challenges globally, compelling healthcare systems to prioritize effective treatment options. Concurrently, ongoing research and developmental activities and clinical trials in the field are intensifying, aimed at innovating new therapies and enhancing the efficacy of existing drugs. Moreover, the regulatory landscape has become more favorable, with a growing number of anti-infective drugs receiving approvals across various regions worldwide. This trend not only expands patient access to essential treatments but also encourages pharmaceutical companies to invest in novel drug development. Thus, these factors collectively boost the anti-infective drugs market, during the forecast period from 2024 to 2030.

4. Who are the key players operating in the anti-infective drugs market?

Some of the key market players operating in the Anti-Infective Drugs are Merck & Co., Inc., Gilead Sciences, Inc., GSK plc., Pfizer Inc., Alembic Pharmaceuticals, Mankind Pharma, Novartis AG, Abbott., Astellas Pharma d.o.o., Bayer AG, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Cipla Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Xellia Pharmaceuticals, AbbVie Inc., Melinta Therapeutics LLC, PACIFIC INDIA PHARMA LIMITED, and others.

5. Which region has the highest share in the anti-infective drugs market?

North America is expected to account for the highest proportion of the anti-infective drugs market in 2023, out of all regions. This can be ascribed to the increasing demand for anti-infective drugs in the region owing to the increasing prevalence of many infectious and targeted diseases, the increasing geriatric patient pool suffering from infectious and targeted diseases, the growing initiatives for the awareness of infectious diseases, the launch of new drugs, and the presence of key market players in the region driving the anti-infective drugs market in North America.

Table of Contents

1. Anti-Infective Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Anti-Infective Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Anti-Infective Drugs Market Key Factors Analysis

• 5.1. Anti-Infective Drugs Market Drivers
  • 5.1.1. The increasing prevalence of various targeted diseases such as healthcare-associated infections, sexually transmitted diseases, respiratory infections, and others.
  • 5.1.2. The increasing research & developmental activities and ongoing clinical trials concerning the anti-infective drugs
  • 5.1.3. The increased number of drug approvals across the globe.
• 5.2. Anti-Infective Drugs Market Restraints and Challenges
  • 5.2.1. The emergence and spread of drug-resistant pathogens along with the side effects
  • 5.2.2. The stringent regulatory approval
• 5.3. Anti-Infective Drugs Market Opportunities
  • 5.3.1. Ongoing research and development in introducing gene therapy in anti-infection drugs

6. Anti-Infective Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Anti-Infective Drugs Market Assessment

• 7.1. By Type
  • 7.1.1. Antibiotics
  • 7.1.2. Antivirals
  • 7.1.3. Antifungals
  • 7.1.4. Others
• 7.2. By Indication
  • 7.2.1. HIV Infection
  • 7.2.2. Pneumonia
  • 7.2.3. Respiratory Viral Infection
  • 7.2.4. Others
• 7.3. By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Topical
  • 7.3.4. Others
• 7.4. Distribution Channel
  • 7.4.1. Hospitals Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. E-Commerce
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.1.2. Canada Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.1.3. Mexico Anti-Infective Drugs Market Size in USD Million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.2.2. Germany Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.2.3. United Kingdom Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.2.4. Italy Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.2.5. Spain Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.2.6. Rest of Europe Anti-Infective Drugs Market Size in USD Million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.3.2. Japan Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.3.3. India Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.3.4. Australia Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.3.5. South Korea Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Anti-Infective Drugs Market Size in USD Million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.4.2. Africa Anti-Infective Drugs Market Size in USD Million (2021-2030)
    • 7.5.4.3. South America Anti-Infective Drugs Market Size in USD Million (2021-2030)

8. Anti-Infective Drugs Market Company and Product Profiles

• 8.1. Merck & Co., Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Gilead Sciences, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GSK plc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Pfizer Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Alembic Pharmaceuticals
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Mankind Pharma
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Novartis AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Abbott.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Astellas Pharma d.o.o.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Bayer AG
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Bristol-Myers Squibb Company
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Sanofi
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Janssen Global Services, LLC
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. F. Hoffmann-La Roche Ltd
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Cipla Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Xellia Pharmaceuticals
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. AbbVie Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Melinta Therapeutics LLC
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. PACIFIC INDIA PHARMA LIMITED
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us